Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Bloomberg’s Michelle Davis joins Dani Burger on “Bloomberg Deals.” Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding…
Tag: Biogen
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise
Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases…
Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The…
Here’s What Analysts Think About Biogen Inc. (BIIB)
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on…
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress
We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported…
AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
Thinkstock It’s likely that the Federal Reserve Chairman Jay Powell will announce a 25-basis-point rate cut this afternoon. Traders are…
Biogen Inc. (BIIB): A Bull Case Theory
We came across a bullish thesis on Biogen Inc. on Investing With Purpose’s Substack. In this article, we will summarize…